About Us
Pioneering science for patient choice
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2-receptor antagonists. By targeting this clinically proven therapeutic target,1,2,3 Pharvaris is advancing new alternatives to injected therapies to potentially help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
Mission
Pharvaris aims to develop novel, oral bradykinin B2 receptor antagonists that potentially improve the standard of care for people living with all types of bradykinin-mediated angioedema.
Vision
Driven by our values, Pharvaris is a leader in bradykinin-mediated diseases and aims to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks.
Legacy and Values
Pharvaris aims to provide oral alternatives that improve the standard of care for people living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Pharvaris is a leader in bradykinin-mediated diseases and our team has a rich history in the rare disease space. Pharvarians are driven by our values:
considering others care-fully
Consider all those impacted by our Mission and what we do
Consider all those impacted by our Mission and what we do
Lead with empathy and consider implications of our actions on others
It’s always “We” not “I”
Create the company around the right people
leading with trust
Trust and respect expertise, experience and decisions made
Trust and respect expertise, experience and decisions made
Be comfortable with vulnerability and committed to being real, authentic and transparent
Know it’s ok to take appropriate risks and sometimes fail, and when necessary to ask for help
Take ownership, responsibility and always take the initiative
ensuring rigor & diversity of thought
Prioritize rigorous, well-informed decision making based on robust critical thinking, pragmatism and productive challenge
Prioritize rigorous, well-informed decision making based on robust critical thinking, pragmatism and productive challenge
Act with professionalism and bring depth of experience and knowledge
Be open-minded and non-judgmental, encouraging and considering diverse perspectives, opinions and ideas
contributing freely
Have the freedom to contribute, knowing we will be listened to, and recognize everyone has a responsibility to speak up
Have the freedom to contribute, knowing we will be listened to, and recognize everyone has a responsibility to speak up
Be free and expected to think differently and creatively
Have the freedom to work in a way which enables us to be our best
Our legacy in the HAE space, our core scientific expertise, and our values drive our passion to provide patients with choice.
Leadership Team
Board of Directors
Corporate and Group Information
This section provides general corporate and group information about Pharvaris N.V. (the "Company" or "Pharvaris") and its subsidiaries (collectively, "The Group"). Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on bradykinin-mediated angioedema and other bradykinin-mediated diseases.
Pharvaris N.V. was incorporated on September 30, 2015, and is based in Leiden, the Netherlands. Pharvaris N.V.'s registered office is located at Emmy Noetherweg 2, Leiden, and has been registered at the Chamber of Commerce under file number 64239411.
Subsidiaries
The subsidiaries include:
| Name | Legal seat | Country of incorporation |
|---|---|---|
| Pharvaris Holdings B.V. | Leiden | The Netherlands |
| Pharvaris Netherlands B.V. | Leiden | The Netherlands |
| Pharvaris, Inc. | Delaware | United States of America |
| Pharvaris GmbH | Zug | Switzerland |
Pharvaris, Inc. and Pharvaris GmbH were incorporated on January 31, 2020, and March 27, 2020, respectively. Pharvaris, Inc. acts as a service provider to the principal Company of the Group. Pharvaris GmbH is the principal Company of the Group starting April 1, 2020. The principal Company owns the Group's intellectual property and makes the major operating decisions.
Parent Company
The ultimate parent company of the Group is Pharvaris N.V., which is based in the Netherlands.